罗匹尼罗治疗帕金森病的安全性评价  

Safety of ropinirole in the treatment of Parkinson′s disease

作　　者：李淑华[1] 苏闻[1] 陈海波[1] 曾湘豫[1] 蔡晓杰[1] 

机构地区：[1]卫生部北京医院神经内科,100730

出　　处：《中华全科医师杂志》2014年第5期383-385,共3页Chinese Journal of General Practitioners

摘　　要：评价罗匹尼罗片剂治疗帕金森病患者的安全性。221例帕金森病患者随机接受罗匹尼罗[最高平均剂量（7.99±2.03）mg/d，109例]或溴隐亭[最高平均剂量（13.35±3.45）mg/d，112例]治疗，为期12周。安全性指标为不良反应、血压、脉搏、实验室检查和心电图。罗匹尼罗组不良反应发生率为34.9％（38例），溴隐亭组不良反应发生率为34.8％（39例），两组不良反应发生率与溴隐亭组间差异无统计学意义（χ2＝0.000，P＝0.995）。罗匹尼罗用于治疗中国帕金森病患者安全性良好。To explore the safety of ropinirole in the treatment of Parkinson′s disease（ PD）.A total of 221 PD patients participated in a multi-center,12-week randomized,bromocriptine-controlled,double-blind, double-dummy and parallel-group trial.The safety was assessed on the basis of adverse reactions , blood pressure,pulse,laboratory parameters and electrocardiography recordings.The incidence of adverse reaction was 34.9%in ropinirole group and 34.8% in bromocriptine group.And the frequency of adverse reactions had no inter-group statistical significance （χ2 =0.000,P=0.995）.Ropinirole has an excellent profile of safety in the treatment of Chinese PD patients.

关 键 词：帕金森病 溴隐亭 罗匹尼罗 

分 类 号：R742.5[医药卫生—神经病学与精神病学]